SCHEMBL4355650

SCHEMBL4355650

Cc1cccc(CNc2cc(Cl)cc(Cl)c2O)c1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.47
BRD9 Q9H8M2 1/20 0.47
MRGPRX4 Q96LA9 1/20 0.45
MEN1 O00255 1/20 0.44
LMNA P02545 1/20 0.44
POLB P06746 1/20 0.44
HPGD P15428 1/20 0.44
KMT2A Q03164 1/20 0.44
CYP1A2 P05177 3/20 0.43
CYP3A4 P08684 3/20 0.43
CYP2D6 P10635 3/20 0.43
CYP2C19 P33261 3/20 0.43
CLK4 Q9HAZ1 3/20 0.43
TSHR P16473 2/20 0.43
CXCR4 P61073 5/20 0.43
CYP2C9 P11712 1/20 0.43
P2RX7 Q99572 1/20 0.43
KCNN3 Q9UGI6 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4346359 0.85 BRD4 (0.49) BRD4BRD9MRGPRX4CYP1A2CYP3A4
SCHEMBL4345563 0.82 BRD4 (0.49) BRD4BRD9MRGPRX4CYP1A2CYP3A4
SCHEMBL4347062 0.81 P2RX7 (0.48) BRD4BRD9MEN1HPGDKMT2A
SCHEMBL4348617 0.80 MEN1 (0.53) MRGPRX4MEN1LMNAHPGDKMT2A
SCHEMBL4356091 0.79 FFAR1 (0.49) MRGPRX4MEN1KMT2A
SCHEMBL17243401 0.78 MRGPRX4 (0.46) BRD4BRD9MRGPRX4LMNAKMT2A
SCHEMBL4351954 0.78 STK39 (0.45) MRGPRX4LMNA
SCHEMBL4350844 0.77 HTT (0.55) MEN1LMNAKMT2A
SCHEMBL27761105 0.77 BRD4 (0.50) BRD4BRD9LMNAHPGDCYP1A2
SCHEMBL27761107 0.77 BRD4 (0.50) BRD4BRD9MRGPRX4MEN1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF JERINI AG (DE) 2011-03-17 US claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP claimed
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors JERINI AG (DE) 2007-03-08 US claimed
CN-1701061-A Novel compounds for inhibiting rotamase enzymes and uses thereof JERINI AG (DE) 2005-11-23 CN claimed
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF JERINI AG (DE) 2011-03-17 US disclosed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF NR1I3, NR1D1, NR1D2 BRD4 2590/4885BRD9 3597/4885MRGPRX4 742/4885
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors NR1I3, NR1D1, NR1D2 BRD4 514/4885BRD9 2070/4885MRGPRX4 795/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.